• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿托伐他汀和呋喃妥因在乳腺癌和神经母细胞瘤细胞中的新用途

Atorvastatin and Nitrofurantoin Repurposed in the Context of Breast Cancer and Neuroblastoma Cells.

作者信息

Moura Catarina, Correia Ana Salomé, Pereira Mariana, Ribeiro Eduarda, Santos Joana, Vale Nuno

机构信息

OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.

CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.

出版信息

Biomedicines. 2023 Mar 15;11(3):903. doi: 10.3390/biomedicines11030903.

DOI:10.3390/biomedicines11030903
PMID:36979882
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10046192/
Abstract

Chemotherapy still plays a central role in the treatment of cancer. However, it is often accompanied by off-target effects that result in severe side-effects and development of drug resistance. The aim of this work was to study the efficacy of different repurposed drugs on the viability of MCF-7 and SH-SY5Y breast cancer and neuroblastoma cells, respectively. In addition, combinations of these repurposed drugs with a classical chemotherapeutic drug (doxorubicin) were also carried out. The cytotoxic effects of the repurposed drugs were evaluated individually and in combination in both cancer cell lines, assessed by MTT assays and morphological evaluation of the cells. The results demonstrated that atorvastatin reduced the viability of both cell lines. However, nitrofurantoin was able to induce cytotoxic effects in MCF-7 cells, but not in SH-SY5Y cells. The combinations of the repurposed drugs with doxorubicin induced a higher inhibition on cell viability than the repurposed drugs individually. The combination of the two repurposed drugs demonstrated that they potentiate each other. Synergism studies revealed that the combination of doxorubicin with the two repurposed drugs was more effective in SH-SY5Y cells, compared to MCF-7 cells. Taken together, our preliminary study highlights the potential use of atorvastatin and nitrofurantoin in the context of breast cancer and neuroblastoma.

摘要

化疗在癌症治疗中仍起着核心作用。然而，它常常伴随着脱靶效应，导致严重的副作用和耐药性的产生。这项工作的目的是分别研究不同的重新利用药物对MCF - 7乳腺癌细胞和SH - SY5Y神经母细胞瘤细胞活力的影响。此外，还将这些重新利用的药物与经典化疗药物（阿霉素）进行了联合使用。通过MTT试验和细胞形态学评估，分别对两种癌细胞系中重新利用药物的细胞毒性作用进行了单独和联合评估。结果表明，阿托伐他汀降低了两种细胞系的活力。然而，呋喃妥因能够在MCF - 7细胞中诱导细胞毒性作用，但在SH - SY5Y细胞中则不能。重新利用的药物与阿霉素联合使用对细胞活力的抑制作用比单独使用重新利用的药物更高。两种重新利用药物的联合表明它们相互增强作用。协同作用研究表明，与MCF - 7细胞相比，阿霉素与两种重新利用药物的联合在SH - SY5Y细胞中更有效。综上所述，我们的初步研究突出了阿托伐他汀和呋喃妥因在乳腺癌和神经母细胞瘤治疗中的潜在应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/7c17bd4bd7ea/biomedicines-11-00903-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/9e4235998b5f/biomedicines-11-00903-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/a2c6a2913497/biomedicines-11-00903-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/4c2d0a31a909/biomedicines-11-00903-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/89f46fc2494b/biomedicines-11-00903-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/d63ca1394ee4/biomedicines-11-00903-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/71d94bc8228e/biomedicines-11-00903-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/b4875af43d15/biomedicines-11-00903-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/9864e81d6ee2/biomedicines-11-00903-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/41e1d567e6d3/biomedicines-11-00903-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/2925862f6cc2/biomedicines-11-00903-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/e510d30f2aac/biomedicines-11-00903-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/0d45f6e69ce7/biomedicines-11-00903-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/ca793197e3f9/biomedicines-11-00903-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/3fb35e1ba67f/biomedicines-11-00903-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/bf6778136169/biomedicines-11-00903-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/e27e97ed93d6/biomedicines-11-00903-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/98a123caff4e/biomedicines-11-00903-g016a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/7c17bd4bd7ea/biomedicines-11-00903-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/9e4235998b5f/biomedicines-11-00903-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/a2c6a2913497/biomedicines-11-00903-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/4c2d0a31a909/biomedicines-11-00903-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/89f46fc2494b/biomedicines-11-00903-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/d63ca1394ee4/biomedicines-11-00903-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/71d94bc8228e/biomedicines-11-00903-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/b4875af43d15/biomedicines-11-00903-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/9864e81d6ee2/biomedicines-11-00903-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/41e1d567e6d3/biomedicines-11-00903-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/2925862f6cc2/biomedicines-11-00903-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/e510d30f2aac/biomedicines-11-00903-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/0d45f6e69ce7/biomedicines-11-00903-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/ca793197e3f9/biomedicines-11-00903-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/3fb35e1ba67f/biomedicines-11-00903-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/bf6778136169/biomedicines-11-00903-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/e27e97ed93d6/biomedicines-11-00903-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/98a123caff4e/biomedicines-11-00903-g016a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1782/10046192/7c17bd4bd7ea/biomedicines-11-00903-g017.jpg

相似文献

1
Atorvastatin and Nitrofurantoin Repurposed in the Context of Breast Cancer and Neuroblastoma Cells.阿托伐他汀和呋喃妥因在乳腺癌和神经母细胞瘤细胞中的新用途
Biomedicines. 2023 Mar 15;11(3):903. doi: 10.3390/biomedicines11030903.
2
Honeybee Venom Synergistically Enhances the Cytotoxic Effect of CNS Drugs in HT-29 Colon and MCF-7 Breast Cancer Cell Lines.蜜蜂毒液协同增强中枢神经系统药物对HT-29结肠癌细胞系和MCF-7乳腺癌细胞系的细胞毒性作用。
Pharmaceutics. 2022 Feb 25;14(3):511. doi: 10.3390/pharmaceutics14030511.
3
Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells.对抗癌症的新策略：使用重新利用药物的药物组合诱导MCF-7乳腺癌细胞和HT-29结肠癌细胞的协同生长抑制
Curr Issues Mol Biol. 2022 Oct 16;44(10):4930-4949. doi: 10.3390/cimb44100335.
4
Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells.药物组合：一种延长药物再利用和乳腺癌及结肠癌细胞上皮-间充质转化的新策略。
Biomolecules. 2022 Jan 23;12(2):190. doi: 10.3390/biom12020190.
5
Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action.抗疟药和中枢神经系统药物与抗肿瘤药物联合应用于 MCF-7 乳腺癌和 HT-29 结肠癌细胞：生物安全性评价及作用机制。
Biomolecules. 2022 Oct 16;12(10):1490. doi: 10.3390/biom12101490.
6
Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs.抗肿瘤药与中枢神经系统药物同时及序贯联合对HT-29结肠癌细胞和MCF-7乳腺癌细胞的协同生长抑制作用
Int J Mol Sci. 2021 Jul 10;22(14):7408. doi: 10.3390/ijms22147408.
7
Allosteric and Orthosteric Activators of mGluR8 Differentially Affect the Chemotherapeutic-Induced Human Neuroblastoma SH-SY5Y Cell Damage: The Impact of Cell Differentiation State.变构和变构激活剂对 mGluR8 的影响不同，从而影响化学治疗诱导的人神经母细胞瘤 SH-SY5Y 细胞损伤：细胞分化状态的影响。
Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):443-451. doi: 10.1111/bcpt.13041. Epub 2018 Jun 29.
8
Neurosteroids enhance the viability of staurosporine and doxorubicin treated differentiated human neuroblastoma SH-SY5Y cells.神经甾体增强了经星形孢菌素和阿霉素处理的分化型人神经母细胞瘤SH-SY5Y细胞的活力。
Pharmacol Rep. 2008 Sep-Oct;60(5):685-91.
9
The Involvement of Hypoxia in the Response of Neuroblastoma Cells to the Exposure of Atorvastatin.缺氧在神经母细胞瘤细胞对阿托伐他汀暴露反应中的作用
Curr Issues Mol Biol. 2023 Apr 11;45(4):3333-3346. doi: 10.3390/cimb45040218.
10
Inhibition of WNT signaling reduces differentiation and induces sensitivity to doxorubicin in human malignant neuroblastoma SH-SY5Y cells.抑制WNT信号传导可降低人恶性神经母细胞瘤SH-SY5Y细胞的分化并诱导其对阿霉素的敏感性。
Anticancer Drugs. 2017 Jun;28(5):469-479. doi: 10.1097/CAD.0000000000000478.

引用本文的文献

1
Cubosomes as Delivery System to Repositioning Nitrofurantoin in Breast Cancer Management.立方液晶纳米粒作为重新定位呋喃妥因用于乳腺癌治疗的递送系统
Drug Des Devel Ther. 2024 Dec 19;18:6173-6184. doi: 10.2147/DDDT.S499068. eCollection 2024.
2
Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry.实验性、临床性和转化性神经精神病学中认知障碍和情绪障碍的神经退行性变
Biomedicines. 2024 Mar 5;12(3):574. doi: 10.3390/biomedicines12030574.

本文引用的文献

1
Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells.重新利用抗病毒药物沙奎那韦单独或与 5-氟尿嘧啶联合用于前列腺癌和肺癌细胞。
Int J Mol Sci. 2022 Oct 13;23(20):12240. doi: 10.3390/ijms232012240.
2
Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma.匹伐他汀和伊维菌素增强紫杉醇对化疗耐药性高级别浆液性癌的疗效。
Cancers (Basel). 2022 Sep 7;14(18):4357. doi: 10.3390/cancers14184357.
3
Independent and Joint Associations of Pessimism, Total Calorie Intake and Acid-Producing Diets with Insomnia Symptoms among Breast Cancer Survivors.
乳腺癌幸存者中，悲观情绪、总热量摄入及产酸饮食与失眠症状的独立及联合关联。
J Clin Med. 2022 May 17;11(10):2828. doi: 10.3390/jcm11102828.
4
Evaluation of synergism in drug combinations and reference models for future orientations in oncology.肿瘤学中药物联合的协同作用评估及未来方向的参考模型
Curr Res Pharmacol Drug Discov. 2022 May 12;3:100110. doi: 10.1016/j.crphar.2022.100110. eCollection 2022.
5
Discovery of Novel Drug Candidates for Alzheimer's Disease by Molecular Network Modeling.通过分子网络建模发现阿尔茨海默病的新型候选药物
Front Aging Neurosci. 2022 Apr 15;14:850217. doi: 10.3389/fnagi.2022.850217. eCollection 2022.
6
Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells.药物组合：一种延长药物再利用和乳腺癌及结肠癌细胞上皮-间充质转化的新策略。
Biomolecules. 2022 Jan 23;12(2):190. doi: 10.3390/biom12020190.
7
Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs.抗肿瘤药与中枢神经系统药物同时及序贯联合对HT-29结肠癌细胞和MCF-7乳腺癌细胞的协同生长抑制作用
Int J Mol Sci. 2021 Jul 10;22(14):7408. doi: 10.3390/ijms22147408.
8
A comprehensive review on alginate-based delivery systems for the delivery of chemotherapeutic agent: Doxorubicin.海藻酸盐基递药系统用于递送化疗药物：多柔比星的全面综述。
Carbohydr Polym. 2021 May 1;259:117696. doi: 10.1016/j.carbpol.2021.117696. Epub 2021 Jan 26.
9
New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells.抗疟药物的新趋势：抗肿瘤药物与抗疟药物对乳腺癌细胞的协同作用。
Biomolecules. 2020 Dec 1;10(12):1623. doi: 10.3390/biom10121623.
10
Statins as Anticancer Agents in the Era of Precision Medicine.他汀类药物作为精准医学时代的抗癌药物。
Clin Cancer Res. 2020 Nov 15;26(22):5791-5800. doi: 10.1158/1078-0432.CCR-20-1967. Epub 2020 Sep 4.